Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.67 |
| ▸ | LYN | P07948 | 9/20 | 0.54 |
| ▸ | SRC | P12931 | 9/20 | 0.54 |
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | HCK | P08631 | 8/20 | 0.54 |
| ▸ | BRAF | P15056 | 8/20 | 0.51 |
| ▸ | INSR | P06213 | 7/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374341 | 0.89 | LCK (0.67) | LCKLYNSRCKDRHCK | |
| SCHEMBL374410 | 0.88 | LCK (0.66) | LCKLYNSRCKDRHCK | |
| SCHEMBL374451 | 0.87 | LCK (0.66) | LCKLYNSRCKDRHCK | |
| SCHEMBL374317 | 0.87 | LCK (0.65) | LCKLYNSRCKDRHCK | |
| SCHEMBL374496 | 0.87 | LCK (0.67) | LCKLYNSRCKDRHCK | |
| SCHEMBL14550183 | 0.85 | LCK (0.63) | LCKLYNSRCKDRHCK | |
| SCHEMBL373994 | 0.85 | LCK (0.63) | LCKLYNSRCKDRHCK | |
| SCHEMBL374492 | 0.85 | LCK (0.70) | LCKSRCKDRBRAFCSF1R | |
| SCHEMBL374179 | 0.85 | LCK (0.67) | LCKLYNSRCKDRHCK | |
| SCHEMBL374255 | 0.85 | LCK (0.64) | LCKLYNSRCKDRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | LCK 120/4885LYN 148/4885SRC 116/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | LCK 120/4885LYN 148/4885SRC 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.